Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

OBJECTIVES: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective treatment for HIV‐1 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking. The primary 24‐week and secondary 48‐week analyses of study GS‐US‐380‐4449 (NCT03405935), which assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggiolo, Franco, Rizzardini, Giuliano, Molina, Jean‐Michel, Pulido, Federico, De Wit, Stephane, Vandekerckhove, Linos, Berenguer, Juan, D'Antoni, Michelle L., Blair, Christiana, Chuck, Susan K., Piontkowsky, David, Martin, Hal, Haubrich, Richard, McNicholl, Ian R., Gallant, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083930/
https://www.ncbi.nlm.nih.gov/pubmed/35527425
http://dx.doi.org/10.1111/hiv.13319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083930/
https://www.ncbi.nlm.nih.gov/pubmed/35527425
http://dx.doi.org/10.1111/hiv.13319

Ejemplares similares